Suppliers and packagers for generic pharmaceutical drug: ELIGLUSTAT TARTRATE

ELIGLUSTAT TARTRATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494	NDA	Genzyme Corporation	58468-0220-1	4 BLISTER PACK in 1 CARTON (58468-0220-1) / 14 CAPSULE in 1 BLISTER PACK	2014-09-03
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494	NDA	Genzyme Corporation	58468-0220-2	1 BLISTER PACK in 1 CARTON (58468-0220-2) / 14 CAPSULE in 1 BLISTER PACK	2014-09-03

Suppliers for the Pharmaceutical Drug: Eliglustat Tartrate

Last updated: July 27, 2025

Introduction

Eliglustat tartrate is a potent and selective oral therapy indicated for adults with Gaucher disease type 1 (GD1), a rare lysosomal storage disorder characterized by deficient activity of the enzyme glucocerebrosidase. The medication primarily acts as a substrate reduction therapy, inhibiting glucosylceramide synthase to reduce substrate accumulation. As a niche yet critical molecule, the supply chain for eliglustat tartrate involves specialized manufacturers, often linked to the original developers and licensed partners, as well as secondary suppliers catering to global markets. This analysis delineates the current landscape of eliglustat tartrate suppliers, examining primary manufacturers, licensing arrangements, manufacturing process nuances, and regional distribution channels.

---

Overview of Eliglustat Tartrate Manufacturing Landscape

The pharmaceutical synthesis of eliglustat tartrate is intricate, reflecting its status as a complex small molecule with stereospecific properties. Its development was pioneered by Sanofi Genzyme, a leading biopharmaceutical company specializing in rare diseases, which secured regulatory approval for the drug under the brand name Cerdelga in multiple markets, including the United States and the European Union.

Primary Suppliers and Manufacturers

1. Sanofi Genzyme

   As the originator, Sanofi Genzyme initially held exclusive rights to produce and supply eliglustat tartrate. The company oversees the manufacturing process, ensuring quality control and regulatory compliance across the supply chain. Sanofi’s internal manufacturing facilities are equipped for large-scale synthesis, and it often contracts with specialized contract manufacturing organizations (CMOs) to meet global demands.

2. Contract Manufacturing Organizations (CMOs)

   Several CMOs globally are engaged by Sanofi for the synthesis and packaging of eliglustat tartrate, seeking to expand manufacturing capacity and regional distribution. Noteworthy CMOs involved in complex chemical syntheses for pharmaceuticals include:

   • Evonik Industries (Germany): Known for fine chemicals and pharmaceutical intermediates, possibly involved in synthesis intermediates.

   • Lonza (Switzerland): Active in contract manufacturing of active pharmaceutical ingredients (APIs), including niche molecules.

   • Boehringer Ingelheim Biopharmaceuticals (Germany): Engaged in complex chemical and biological manufacturing, likely providing intermediates or final API synthesis.

   It is pertinent to note that Sanofi maintains strict quality and regulatory standards, making the selection of CMOs a strategic decision primarily based on compliance, capacity, and geographic proximity.

3. Licensed and Authorized Suppliers

   As of the latest available public data, Sanofi retains exclusive manufacturing rights for eliglustat tartrate in most markets. However, licensing agreements and strategic partnerships could enable select regional manufacturers, especially in emerging markets, to produce or import the molecule under authorized channels. These relationships are often confidential owing to competitive and regulatory sensitivities.

---

Regional Supply Dynamics

• United States & Europe

  Within the US and EU, Sanofi acts as the sole official supplier for eliglustat tartrate. Distribution is managed through Sanofi’s extensive network of distributors and specialty pharmacies. No publicly available evidence suggests the presence of alternative licensed suppliers within these regions.

• Emerging Markets

  In regions like Latin America, Southeast Asia, and Africa, Sanofi’s licensing agreements with regional distributors serve to facilitate clinical and commercial supply. Local pharmaceutical companies often import the drug as part of Sanofi’s authorized supply chain or have regulatory approvals to manufacture generic or biosimilar versions, though none have attained Regulatory Agency approval specifically for eliglustat tartrate as of 2023.

• Supply Chain Challenges

  The complexity of eliglustat tartrate synthesis and the need for strict quality standards limit the number of authorized manufacturers capable of producing the API. Consequently, supply constraints could become problematic, especially during periods of increased demand or manufacturing disruptions.

---

Implications for Pharmaceutical Suppliers and Stakeholders

• Limited Market Suppliers

  The exclusivity held by Sanofi and its vetted CMOs frames Eliglustat tartrate’s supply landscape as highly concentrated and technically sophisticated. For new entrants or alternative suppliers, entering this niche requires overcoming significant regulatory, technical, and quality hurdles.

• Secondary Market Risks

  Unregulated or counterfeit supplies of eliglustat tartrate pose serious safety risks. Stakeholders should verify supplier credentials, regulatory approvals, and compliance with Good Manufacturing Practices (GMP) before procurement.

• Strategic Importance of Supply Chain Resilience

  Companies and healthcare systems reliant on eliglustat tartrate should develop risk mitigation strategies, including securing multiple certified suppliers and maintaining inventory buffers, given the specialized manufacturing and sourcing complexities.

---

Conclusion

The supply landscape for eliglustat tartrate remains predominantly under the control of Sanofi Genzyme, leveraging a network of specialized CMOs for manufacturing. While regional licensing exists to facilitate market access, there are no widely recognized secondary suppliers or generic alternatives officially approved. As a critical therapy for Gaucher disease type 1, ensuring robustness and integrity in the supply chain is vital for sustained patient access.

---

Key Takeaways

• Primary control of eliglustat tartrate production resides with Sanofi Genzyme, utilizing a network of trusted CMOs.
• Regional licensing arrangements support distribution in emerging markets, though no generic or alternative approved suppliers are publicly documented.
• Supply chain complexity limits the number of capable manufacturers, heightening risks of shortages and counterfeit products.
• Stakeholders should prioritize verified, GMP-compliant sources and monitor geopolitical or manufacturing disruptions affecting supply.
• Future market entrants need significant regulatory approval and technical capacity to participate in eliglustat tartrate manufacturing at an authorized level.

---

FAQs

1. Who are the primary manufacturers of eliglustat tartrate?
   Sanofi Genzyme holds the primary manufacturing rights, working with specialized CMOs such as Evonik, Lonza, and Boehringer Ingelheim, though detailed partnerships are typically confidential.

2. Can other pharmaceutical companies produce eliglustat tartrate?
   Currently, no publicly available licensed manufacturers beyond Sanofi are producing eliglustat tartrate for commercial distribution. Entry into this niche requires substantial regulatory and technical approval.

3. Are there generic versions of eliglustat tartrate available?
   No generic eliglustat tartrate has been approved; the drug remains under patent and proprietary manufacturing controlled by Sanofi.

4. How can pharma stakeholders ensure the integrity of eliglustat tartrate supply?
   Stakeholders should verify sources through regulatory approvals, quality certifications, and adherence to GMP standards, avoiding unverified imports or counterfeit products.

5. What are the supply chain risks associated with eliglustat tartrate?
   The complex synthesis process, limited number of capable manufacturers, and geographical concentration of production present risks of shortages, disruptions due to manufacturing issues, or geopolitical factors.

---

Sources

1. [1] Sanofi Genzyme. Cerdelga (Eliglustat) Prescribing Information.
2. [2] European Medicines Agency. Cerdelga Summary of Product Characteristics.
3. [3] U.S. Food & Drug Administration. Cerdelga (Eliglustat) Approved Labeling.
4. [4] Industry reports on pharmaceutical manufacturing and supply chain logistics (publicly available).
5. [5] Contract manufacturing organization data sheets and press releases.